Infusion-related hypersensitivity reactions during natalizumab treatment.
Phillips
J T
JT
Multiple Sclerosis Center at Texas Neurology, Dallas, TX 75214, USA. JTPhillips@TexasNeurology.com
O'Connor
P W
PW
Havrdova
E
E
Hutchinson
M
M
Kappos
L
L
Miller
D H
DH
Polman
C H
CH
Lublin
F D
FD
Giovannoni
G
G
Wajgt
A
A
Lynn
F
F
Panzara
M A
MA
Sandrock
A W
AW
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology; D061067:Antibodies, Monoclonal, Humanized; D002395:Catecholamines / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000276:immunology / Q000503:physiopathology*; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects; D008991:Monitoring, Physiologic / Q000592:standards; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D013997:Time Factors; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D002395:Catecholamines; D006634:Histamine H1 Antagonists; D000069442:Natalizumab